Outcome of Recurrent and Metastatic Small Cell Carcinoma of the Bladder

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2009 Jun 9

PMID 19500382

Citations 23

Authors

Nabil Ismaili

Pierre Etienne Heudel

Fadi Elkarak

Wafaa Kaikani

Agathe Bajard

Mohammed Ismaili

Hassan Errihani

Jean Pierre Droz

Aude Flechon

Affiliations

Soon will be listed here.

Abstract

Background: Bladder small cell carcinoma is an uncommon tumour. Through a retrospective study we will present the evolution of recurrent and metastatic disease and outcome of patients treated at Léon-Bérard Cancer Centre.

Methods: Only 15 patients having recurrent or metastatic bladder small cell carcinoma were treated at Léon-Bérard Cancer Centre between 1996 and 2007. The patients were divided in two groups: a mixed small cell carcinoma group (9 patients) and a pure small cell carcinoma group (6 patients). All the records and informations related to treatment and outcome of the 15 patients were retrospectively analyzed. Various characteristics of small cell carcinoma were investigated.

Results: The median age of the 15 patients having recurrent or metastatic bladder small cell carcinoma and treated at Léon-Bérard Cancer Centre was 63 years and the disease was at stage IV for all cases. Nine patients were treated by chemotherapy. Four patients were treated by local radiotherapy (3 with radiotherapy without previous surgery and 1 with surgery followed by radiotherapy) and chemotherapy. One patient was treated by whole brain radiotherapy. And one patient died before treatment. After 52.4 months median follow up, 12 patients died. Median overall survival was 7.6 months. Survival probability at 1 year was 33%. Median overall survival was 9.9 months in the mixed small cell carcinoma group, and was only 4.6 months in the pure small cell carcinoma group. Survival probability at 1 year in the mixed small cell carcinoma group was 44% as compared to 17% in the pure small cell carcinoma group (Log-rank test: p = 0.228).

Conclusion: Recurrent and metastatic bladder small cell carcinoma is associated with very poor prognosis. The pure bladder small cell carcinoma appears to have poorer outcome than the mixed bladder small cell carcinoma. Chemotherapy using platinum drugs is a mainstay treatment.

Citing Articles

Small cell bladder carcinoma treated with nivolumab as adjuvant maintenance therapy.

Kitamura K, Nonami T, Muto S, Horie S BMJ Case Rep. 2023; 16(12).

PMID: 38160025 PMC: 10759028. DOI: 10.1136/bcr-2023-257402.

Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment.

Hyung J, Kim H, Kim G, Cho Y, Ryu Y, Kim S Cancer Res Treat. 2023; 56(2):624-633.

PMID: 38037320 PMC: 11016647. DOI: 10.4143/crt.2023.1076.

Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab.

Kamitani R, Ando T, Hanai K, Tanaka A, Kashizaki F, Sekido Y BMC Urol. 2022; 22(1):170.

PMID: 36335330 PMC: 9637296. DOI: 10.1186/s12894-022-01130-4.

Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.

Teo M, Guercio B, Arora A, Hao X, Regazzi A, Donahue T Clin Genitourin Cancer. 2022; 20(5):431-441.

PMID: 35676169 PMC: 9809986. DOI: 10.1016/j.clgc.2022.05.005.

Complexities of Contemporary Bladder Cancer Care: NYU Case of the Month, September 2019.

Matulewicz R Rev Urol. 2020; 21(4):172-174.

PMID: 32071566 PMC: 7020279.

References

Pan C, Yang X, Lopez-Beltran A, MacLennan G, Eble J, Koch M . c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol. 2004; 18(3):320-3. DOI: 10.1038/modpathol.3800318. View

Lohrisch C, Murray N, Pickles T, Sullivan L . Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer. 1999; 86(11):2346-52. DOI: 10.1002/(sici)1097-0142(19991201)86:11<2346::aid-cncr24>3.0.co;2-5. View

Jackman D, Johnson B . Small-cell lung cancer. Lancet. 2005; 366(9494):1385-96. DOI: 10.1016/S0140-6736(05)67569-1. View

Roth B, Johnson D, Einhorn L, Schacter L, Cherng N, Cohen H . Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992; 10(2):282-91. DOI: 10.1200/JCO.1992.10.2.282. View

Cramer S, Aikawa M, Cebelin M . Neurosecretory granules in small cell invasive carcinoma of the urinary bladder. Cancer. 1981; 47(4):724-30. DOI: 10.1002/1097-0142(19810215)47:4<724::aid-cncr2820470417>3.0.co;2-2. View

Choong N, Quevedo J, Kaur J . Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005; 103(6):1172-8. DOI: 10.1002/cncr.20903. View

Ismaili N, Arifi S, Flechon A, El Mesbahi O, Blay J, Droz J . Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. Bull Cancer. 2009; 96(6):E30-44. DOI: 10.1684/bdc.2009.0883. View

Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A . Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002; 346(2):85-91. DOI: 10.1056/NEJMoa003034. View

Cheng L, Pan C, Yang X, Lopez-Beltran A, MacLennan G, Lin H . Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer. 2004; 101(5):957-62. DOI: 10.1002/cncr.20456. View

10.

Christopher M, Seftel A, Sorenson K, Resnick M . Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic and clinicopathological study. J Urol. 1991; 146(2):382-8. DOI: 10.1016/s0022-5347(17)37800-x. View

11.

Grignon D, Ro J, Ayala A, Shum D, Ordonez N, Logothetis C . Small cell carcinoma of the urinary bladder. A clinicopathologic analysis of 22 cases. Cancer. 1992; 69(2):527-36. DOI: 10.1002/1097-0142(19920115)69:2<527::aid-cncr2820690241>3.0.co;2-7. View

12.

Johnson B, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S . Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003; 9(16 Pt 1):5880-7. View

13.

Holmang S, Borghede G, Johansson S . Primary small cell carcinoma of the bladder: a report of 25 cases. J Urol. 1995; 153(6):1820-2. View

14.

Jones T, Kernek K, Yang X, Lopez-Beltran A, MacLennan G, Eble J . Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol. 2005; 36(7):718-23. DOI: 10.1016/j.humpath.2005.04.007. View

15.

Ismaili N, Elkarak F, Heudel P, Flechon A, Droz J . Small cell cancer of the bladder: The Leon-Berard cancer centre experience. Indian J Urol. 2009; 24(4):494-7. PMC: 2684383. DOI: 10.4103/0970-1591.44255. View

16.

Spigel D, Hainsworth J, Simons L, Meng C, Burris 3rd H, Yardley D . Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thorac Oncol. 2007; 2(9):854-61. DOI: 10.1097/JTO.0b013e31814617b7. View

17.

Wang X, Zhang S, MacLennan G, Eble J, Lopez-Beltran A, Yang X . Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 2007; 13(3):953-7. DOI: 10.1158/1078-0432.CCR-06-2167. View

18.

Siefker-Radtke A, Dinney C, Abrahams N, Moran C, Shen Y, Pisters L . Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004; 172(2):481-4. DOI: 10.1097/01.ju.0000132413.85866.fc. View

19.

Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T . Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991; 83(12):855-61. DOI: 10.1093/jnci/83.12.855. View

20.

Agoff S, Lamps L, Philip A, Amin M, Schmidt R, True L . Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000; 13(3):238-42. DOI: 10.1038/modpathol.3880044. View